This will be a Phase 1 Open-Label, dose escalation and expansion study of MT-0169 (an Engineered toxin body (ETB) in patients with relapsed or refractory multiple myeloma or non-Hodgkin lymphoma.
This trial is currently open and accepting patients.
The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required.
Inclusion Criteria Part 1 (RRMM patients only)
Inclusion criteria Part 2 (both RRMM and RRNHL patients)
Exclusion Criteria for Part 1 (RRMM patients only):
Exclusion Criteria for Part 2 RRMM patients only:
Exclusion Criteria for Part 2 (both RRMM and NHL patients):
Enrollment: 144 patients (estimated)View More
View all clinical trial locations sorted by state.
Read the latest news and updates on this trial.
If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.
You can explore trial locations from around the US and connect directly with a trial coordinator.Find Nearby Locations
You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.
Still need help? Send us a message